Glemlin Mxr 12.5/2.5/1000mg 14s
Empagliflozin, linagliptin, and metformin XR 12.5/2.5/1000mg for type 2 diabetes.
Glemlin Mxr 12.5/2.5/1000mg combines empagliflozin (SGLT2), linagliptin (DPP-4), and metformin in extended-release formulation for type 2 diabetes. Used when triple therapy is needed. Take once or twice daily with meals as directed; swallow whole.
Purpose
Treatment of type 2 diabetes mellitus as adjunct to diet and exercise when triple therapy is appropriate.
Ingredients
Empagliflozin 12.5mg, linagliptin 2.5mg, and metformin hydrochloride 1000mg (extended-release) per tablet.
Warnings
Contraindicated in severe renal impairment and diabetic ketoacidosis. Not for type 1 diabetes. Risk of genital and urinary infections.
Side Effects
Nausea, diarrhoea, urinary tract infections, genital mycotic infections. Rare: ketoacidosis. Report unusual tiredness or abdominal pain.
Storage Instructions
Store below 30°C in a dry place. Keep in original pack; protect from moisture.
| Brand | Nabiqasim |
| Status | Active |
Related Products
